Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
This study aimed to investigate the risk factors for outcomes in maintenance hemodialysis (MHD) patients after COVID-19 infection.
A single-center retrospective cohort study was conducted. Adult MHD patients from Huashan Hospital, Fudan University, who contracted COVID-19 between December 2022 and February 2023 were enrolled. Exclusion criteria included incomplete follow-up data. Univariate and multivariate Logistic regression analyses were used to evaluate the risk factors for outcomes in MHD patients following COVID-19 infection.
A total of 154 MHD patients with COVID-19 infection were included in the analysis. The mean age of the cohort was 64 years, and 48% were male. The primary renal disease was chronic glomerulonephritis in 50% of the patients, while the proportions of patients with comorbid diabetes and hypertension were 25% and 63%, respectively. Follow-up showed that the patients' pre-dialysis fingertip oxygen saturation dropped to its lowest level around day 10 post-infection on average, before gradually increasing. Post-COVID-19 infection, there was a more severe tendency for clotting in the dialyzer and tubing. The dosage of low molecular weight heparin (LMWH) began to be increased based on the clotting status of the dialyzer and tubing around day 10 on average. 67% of COVID-19 positive patients required a 12% increase in LMWH dosage, which persisted for over 2 weeks. Comparison of biochemical tests before and after infection showed that, on average, hemoglobin decreased, prothrombin time (PT) shortened, serum carbon dioxide combining power decreased, while serum globulin and sodium concentrations increased in MHD patients after COVID-19 infection. Using a composite endpoint of death, hospitalization, or oxygen saturation below 97.5%, 23 patients experienced the composite endpoint event. Multivariate Logistic regression analysis indicated that age, presence of diabetes, pre-infection high-sensitivity C-reactive protein (hs-CRP) level, and whether the LMWH dosage was increased were significant risk factors for poor prognosis in MHD patients with COVID-19 infection. A greater increase in the LMWH dose was associated with worse outcomes in MHD patients with COVID-19.
Advanced age, comorbid diabetes, high hs-CRP level, and an increased LMWH dosage are risk factors for poor prognosis in MHD patients with COVID-19 infection. The passive increase in LMWH dosage reflects the hypercoagulable state induced by COVID-19 infection, the mechanism of which is related to the severe vascular endothelial injury caused by the virus. Therefore, actively administering anticoagulation therapy based on the clotting status of the dialyzer and tubing in MHD patients may help improve poor clinical outcomes and reduce the occurrence of cardiovascular events.
